Widespread GLP-1 medication use shifts American consumer spending

With an estimated 11% of American adults now using GLP-1 medications for weight management, the economic ripple effects are becoming increasingly visible. Industry analysis from PwC indicates that users frequently shift their spending habits after six to eight months of treatment, moving away from quick-service restaurants and processed snacks toward higher-quality clothing, fresh produce, and protein-dense grocery items.

The fitness industry has also felt the impact. While overall activity levels among users remain high, preferences have shifted toward strength and functional training to combat potential muscle mass loss, prompting fitness chains to redesign their facilities. Concurrently, the airline industry is monitoring potential fuel savings as passengers lose weight, though this may be offset by shifts in in-flight purchase behaviors.

Despite these trends, the longevity of these spending patterns remains uncertain. Business owners, particularly in sectors like bespoke tailoring, report that the volatility in patient weight—often caused by regaining weight after stopping medication—creates operational challenges. Analysts suggest that while the current shift is substantial, the long-term impact on the broader economy will depend on the sustained use of these medications.